Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

poLight ASA – follow-up purchase order for barcode scan engine product

Horten, 9 august 2021 - poLight ASA (OSE: PLT) today announced that the company has received a purchase order for TLens of approximately NOK 1,450,000. The purchase order is related to the barcode scan engine product already released to the market. The purchase order is expected to be delivered within end of Q1-2022. “This customer forms an important basis for us in the barcode segment. We expect to grow our customer base in this area in the future“, said Dr. Øyvind Isaksen, the CEO of poLight.

Zalaris UK awarded Most Outstanding Payroll and HR Solutions Provider of the Year 2021

Zalaris ASA, a leading provider of Outsourced Payroll and HR services, is happy to announce it has been recognised as the winner of “The Most Outstanding Payroll and HR Solutions Provider of the Year 2021”.Awarded by CEO Monthly magazine as part of their 2021 Business Elite Awards. Read more about the awards here . The award recognises Zalaris’ cost-effective payroll solution which simplifies complex HR & Payroll processes with the ability to seamlessly integrate with all major HRIS systems and other third-party solution, whilst ensuring

New real-world driving tests with Triboron show significant reduction of fuel consumption and CO\2\ emissions

Triboron International AB (publ) (”Triboron"), in collaboration with the leading UK testing company Emissions Analytics, has conducted Real Driving Emissions (”RDE”) tests that show significant reduction in both fuel consumption and CO\2\ emissions.Euro 6 standardsWhen the Euro 6 standard was introduced in the EU in September 2015, cars were tested for emissions in a laboratory. These tests that were known to be unrealistic when compared with real-world driving and cars could also be optimized to perform particularly well in laboratory settings. To ensure even cleaner cars, the EU

Diamyd Medical secures precision medicine patent for prevention and treatment of autoimmune diabetes

The European Patent Office has informed Diamyd Medical that the Company’s patent application regarding prevention and treatment of autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene will be granted. The patent is valid until 2035 and provides central protection in Europe for the treatment or prevention of genetically defined autoimumune diabetes using GAD, which is the active component in the therapeutic diabetes vaccine Diamyd[®]. The patent claims cover the patient population in which Diamyd[®] has shown efficacy and is targeted in the upcoming Phase III trial DIAGNODE-3.“

Invitation to presentation of Balco’s second quarter report 2021

Balco’s interim report for the second quarter 2021 will be published at 07:30 CET on August 18, 2021. A web-cast telephone conference will be held at 09:00 CET the same day, where CEO and President Kenneth Lundahl and CFO Michael Grindborn will present the results for the second quarter 2021.A possibility will be given to ask questions via the webcast and follow the presentation material live. The webcast, which afterwards also will be available on demand, will be accessible at Balco’s financial website, www.balcogroup.se or via the following link: https://tv.streamfabriken.com/balco-q2-

Forxiga approved in the EU for CKD

09 August 2021 07:05 BST Forxiga approved in the EU for the treatment of chronic kidney disease in patients with and without type-2 diabetes Approval based on unprecedented DAPA-CKD Phase III data is the most significant advancement in chronic kidney disease in more than 20 years AstraZeneca's Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The approval by the European Commission is based on positive results

2020 Bulkers Ltd. (2020) – Invitation to webcast and conference call Q2 2021 results

2020 Bulkers Ltd. will release its financial results for the second quarter of 2021 on Wednesday, August 11, 2021. A conference call and webcast will be held at 3:00 PM CET. The earnings report and presentation will be available from the Investor Relations section on www.2020bulkers.com on the same day. In order to listen to the presentation, you may do one of the following: Listen-only webcast (including the slide presentation): https://edge.media-server.com/mmc/p/9cv4wvv4 or you can click the “Webcast” link on www.2020bulkers.com/investor-relations/ Conference Call: Dial in

Panoro Energy – Block G Equatorial Guinea update

Oslo, 9 August 2021 – Panoro Energy ASA (“Panoro”) notes the operations update issued today by joint venture partner Kosmos Energy in relation to the producing Block G (Ceiba field and Okume Complex), offshore Equatorial Guinea, where Panoro holds a 14.25% Working Interest. Gross production at Block G averaged 29,100 bopd in the second quarter. The Okume upgrade project is expected to be completed in the fourth quarter and will contribute additional power, water injection and gas lift capacity necessary for further de-bottlenecking of the facilities and additional electrical

Graphene binds drugs which kill bacteria on implants

Bacterial infections relating to medical implants place a huge burden on healthcare and cause great suffering to patients worldwide. Now, researchers at Chalmers University of Technology, Sweden, have developed a new method to prevent such infections, by covering a graphene-based material with bactericidal molecules. “Through our research, we have succeeded in binding water-insoluble antibacterial molecules to the graphene, and having the molecules release in a controlled, continuous manner from the material” says Santosh Pandit, researcher at the Department of Biology and

Flexion Mobile signs Top-tier title Evony The King's Return

Currently the highest grossing Google Play title in Flexion's growing portfolioLONDON, 9th of August, 2021 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has signed a distribution agreement with Top Games Inc for their top grossing game Evony the King's Return, the hot real-time strategy MMO of 2021. Flexion will distribute the game in all its channels including Amazon, Samsung, Huawei, and ONEstore. According to Sensor Tower, the game generated approx. USD 8 million to the developer in Google Play in July. This makes it Flexion's

Invitation to half year 2021 business review briefing

Remedy Entertainment Plc | Press release 9:00 pm (EEST) 9 August 2021 Invitation to half year 2021 business review briefing Remedy will publish its business review of April–June 2021 on Friday 13 August 2021 at 09:00 am (EEST) at https://investors.remedygames.com/announcements-and-releases/ The company will host an English language briefing webcast and conference call on the same day at 11:00 am (EEST). Remedy’s business review will be presented by CEO Tero Virtala and CFO Terhi Kauppi. The presentation will be followed by a Q&A session for investors, analysts, and media.

Quickbit selects Worldpay from FIS for merchant acquiring services

Quickbit has entered into an agreement with Worldpay from FIS to provide global merchant acquiring and related services for card-to-crypto purchases. Worldpay is a leading provider of payment processing solutions with extensive experience and knowledge of cryptocurrencies.Worldpay is part of Fidelity National Information Services, Inc. (NYSE:FIS), a leading provider of technology solutions for merchants, banks and capital markets firms globally. For more information about FIS, please go to https://www.fisglobal.com/en/about-us “We are particularly pleased to be partnering with a leading

Calliditas Receives FDA Fast Track Designation for setanaxib in PBC

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for its lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US and Europe.The FDA Fast Track program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions and that demonstrate

Enhertu head-to-head trial meets primary endpoint

9 August 2021 07:00 BST Enhertu significantly improved progression-free survival in DESTINY-Breast03head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer IDMC recommended unblinding based on primary efficacy endpoint demonstrating superiority; results also indicate strong trend toward improved overall survival Plans for global regulatory submissions underway Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo

Christian Stendevad will take up the position as CEO of Penneo on 18 August 2021

Company Announcement No. 18-2021Copenhagen, 9 August 2021 Christian Stendevad will take up the position as CEO of Penneo on 18 August 2021. Christian Stendevad succeeds Nicolaj Højer Nielsen who will step down as Interim CEO. Nicolaj Højer Nielsen will present the Interim report on the date of publication 27 August 2021 and will be available for queries until 1 September 2021.  As announced in Company Announcement no. 5-2021, Christian Stendevad was appointed CEO of Penneo and would take up the position no later than 1 October 2021.  Christian Sagild, Chairman of the Board

Skanska invests EUR 69M, about SEK 700M, in a new office project in Warsaw, Poland

Skanska invests EUR 69M, about SEK 700M, in the first phase of Studio, an office complex in Warsaw, Poland. The first building will offer a total leasable area of 17,600 square meters and will be 14 stories high.The office complex Studio consists of two buildings and will be delivered in two phases. The total project will offer a total leasable area of approximately 43,000 square meters as well as 286 underground parking places for cars and 285 for bicycles. It will be located between Prosta and Łucka Streets, next to two metro stations (Daszyński and ONZ Roundabouts). The project will

INVITATION TO TELECONFERENCE/AUDIO TRANSMISSION

Concordia Maritime welcomes you to participate in a teleconference/ audio transmission August 12 2021, at 04.00 pm CEST. The Interim Report for Q2 2021 (published August 12 2021) will be presented and questions answered.Presiding:Kim Ullman, CEOMartin Nerfeldt, CFOThe teleconference will be available at:SE: +46856642705UK: +443333009266US: +16467224902To access the audio transmission, please click on the link below:https://tv.streamfabriken.com/concordia-maritime-q2-2021Questions can be posed verbally via the teleconference, or in writing via the audio

AGL and Wärtsilä advance frame agreement with first energy storage project on path to grid decarbonisation

Wärtsilä Corporation, Press release, 9 August 2021 at 8:00 AM EESTThe technology group Wärtsilä will supply a battery energy storage system (BESS) to AGL Energy Limited, one of Australia’s leading integrated energy companies. The 250 MW / 250 MWh system will be installed at the Torrens Island in South Australia. It will be AGL’s first grid-scale BESS project, and the second biggest in Australia. When installed, the system will support a broad portfolio of generating assets, both thermal and renewable, and help Australia to decarbonise and transition towards 100% renewable energy future. The

Positive safety and efficacy outcome of the COVID-19 clinical Phase I/II study for the ABNCoV2 vaccine

Hørsholm, Denmark, August 09, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that COUGH-1, the COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine, as headline results has met its safety and efficacy endpoints with excellent virus neutralization levels of up to 12 times higher compared to the levels achieved after COVID-19 infection. This is significantly higher than the virus neutralization levels reported for leading mRNA COVID-19 vaccines reaching only up to 4.1 times higher than the levels achieved after COVID-19

Swedavia’s traffic statistics for July 2021

In July, more than 1.4 million passengers flew via Swedavia’s ten airports, which corresponds to a decrease of over 60 per cent compared to the same period before the pandemic, July 2019. However, the demand for flights continues to recover with more people being given the opportunity to travel as societies open up and vaccination programmes are rolled out. Meanwhile, the EU’s new digital Covid travel certificate creates conditions for smoother travel if control procedures can be further harmonised in the EU. “Air traffic continues to recover and in July, for the first time since

Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2021 results, Wednesday 18 August

Oslo, Norway, 9 August 2021 - Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2021 results on Wednesday 18 August 2021. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 am CET.The results report and the presentation will be available at www.targovax.com  in the Investors section from 07:00 am CET. Presentation As a consequence of the Corona situation, there will only be a virtual presentation of the results with a live webcast 18 August at 10.00 am CET.

Brighter carries out a private placement of 39.7 MSEK

The Board of Directors of Brighter has, under the authorization from the AGM of 2020, decided on a new share issue of a total of 39.7 MSEK. Payment will be made in cash. The amount of cash received will be used in full to repay previous loans from these lenders and the right to participate in the issue is only given to the lenders. The reasons for the deviation from the shareholders' preferential rights are to strengthen the company's financial position, which the issue is deemed to entail.   Issue terms:  · 10% discount on the lowest volume-weighted average price of the share

Veoneer to Engage in Discussions with Qualcomm

Stockholm, Sweden, August 8, 2021 – The automotive technology company Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), today announced that Veoneer’s board of directors has determined that Qualcomm’s proposal to acquire Veoneer (the “Qualcomm Proposal”) would reasonably be expected to result in a “Superior Proposal”, as defined under the terms of Veoneer’s merger agreement with Magna (the “Merger Agreement”). As a result of the Board’s determination, Veoneer may under the terms of the Merger Agreement engage in discussions with Qualcomm based on the Qualcomm Proposal and Veoneer intends to do

There are no items matching the current filter
There are no more items matching the current filter
Back to top